ERLEADA® for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Among all AR inhibitors FDA approved to treat nmCRPC:
ERLEADA® is the FIRST AND ONLY to deliver a 2-year improvement in median MFS
(ERLEADA® + ADT vs placebo + ADT; 40.5 months vs 16.2 months; HR=0.28; 95% CI: 0.23, 0.35; P<0.0001)1
ERLEADA® improved median overall survival by 14 months:
ERLEADA® is the FIRST AND ONLY therapy to improve median overall survival by more than 1 year in nmCRPC
(ERLEADA® + ADT vs placebo + ADT; 73.9 months [6.2 years] vs 59.9 months [5 years]; HR=0.78; 95% CI: 0.64, 0.96; P=0.0161)*1
ADT = androgen deprivation therapy; CI = confidence interval; FDA = US Food and Drug Administration; HR = hazard ratio; MFS = metastasis-free survival; nmCRPC = non-metastatic castration-resistant prostate cancer; SPARTAN = Selective Prostate Androgen Receptor Targeting with ARN-509.
1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.